Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)Depreciation ExpenseEBIATOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Issued
Ratios

InMed Pharmaceuticals (INM) Depreciation & Amortization (IS) (2021 - 2025)

Historic Depreciation & Amortization (IS) for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to $53202.0.

  • InMed Pharmaceuticals' Depreciation & Amortization (IS) fell 252.29% to $53202.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $211462.0, marking a year-over-year decrease of 359.48%. This contributed to the annual value of $212839.0 for FY2025, which is 307.88% down from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Depreciation & Amortization (IS) of $53202.0 as of Q3 2025, which was down 252.29% from $52752.0 recorded in Q2 2025.
  • InMed Pharmaceuticals' 5-year Depreciation & Amortization (IS) high stood at $55234.0 for Q4 2023, and its period low was $28532.0 during Q3 2021.
  • In the last 5 years, InMed Pharmaceuticals' Depreciation & Amortization (IS) had a median value of $53202.0 in 2024 and averaged $51385.1.
  • As far as peak fluctuations go, InMed Pharmaceuticals' Depreciation & Amortization (IS) soared by 7190.52% in 2022, and later crashed by 497.0% in 2023.
  • Quarter analysis of 5 years shows InMed Pharmaceuticals' Depreciation & Amortization (IS) stood at $49797.0 in 2021, then fell by 1.5% to $49049.0 in 2022, then grew by 12.61% to $55234.0 in 2023, then decreased by 3.68% to $53202.0 in 2024, then changed by 0.0% to $53202.0 in 2025.
  • Its Depreciation & Amortization (IS) was $53202.0 in Q3 2025, compared to $52752.0 in Q2 2025 and $52306.0 in Q1 2025.